• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

    1/10/24 4:15:19 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email
    SC 13G/A 1 p24-0016sc13ga.htm SIGHT SCIENCES, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Sight Sciences, Inc.

    (Name of Issuer)
     

    Common Stock, $0.001 par value

    (Title of Class of Securities)
     

    82657M105

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G/A is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 82657M10513G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    D1 Capital Partners L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 82657M10513G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Daniel Sundheim

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

    CUSIP No. 82657M10513G/APage 4 of 7 Pages

     

    Item 1(a). Name of Issuer.
       
      Sight Sciences, Inc. (the "Issuer")

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
       
     

    4040 Campbell Avenue, Suite 100

    Menlo Park, CA 94025

     

    Item 2(a). Name of Person Filing.
       
     

    This statement is filed by D1 Capital Partners L.P. (the "Investment Manager") and Daniel Sundheim (the "Mr. Sundheim"). The foregoing persons are hereinafter sometimes referred to as the "Reporting Persons."

     

    The Investment Manager is a registered investment adviser and serves as the investment manager of private investment vehicles and accounts (the "Investment Vehicles"), and may have been deemed to beneficially own the shares of Common Stock that were held by the Investment Vehicles. Mr. Sundheim indirectly controls the Investment Manager and may have been deemed to beneficially own the shares of Common Stock that were held by the Investment Vehicles.

     

    Item 2(b). Address of Principal Business Office.
       
     

    D1 Capital Partners L.P.

    9 West 57th Street, 36th Floor

    New York, New York 10019

     

    Daniel Sundheim

    c/o D1 Capital Partners L.P.

    9 West 57th Street, 36th Floor

    New York, New York 10019

     

    Item 2(c). Place of Organization.
       
     

    Investment Manager – Delaware

    Mr. Sundheim – United States of America

     

    Item 2(d). Title of Class of Securities.
       
      Common stock, $0.001 par value (the "Common Stock")

     

    Item 2(e). CUSIP Number.
       
      82657M105

     

     

    CUSIP No. 82657M10513G/APage 5 of 7 Pages

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) x

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    Item 4. Ownership.
       
      The information required by Items 4(a) - (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

     

    CUSIP No. 82657M10513G/APage 6 of 7 Pages

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.  
         
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 82657M10513G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: January 10, 2024  
      D1 Capital Partners L.P.
       
      By: /s/ Amanda Hector
      Name:  Amanda Hector   
      Title:    General Counsel and Chief Compliance Officer
       
       
       
      /s/ Daniel Sundheim
      DANIEL SUNDHEIM

     

    Get the next $SGHT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    7/10/2023$15.00 → $9.00Buy → Neutral
    Citigroup
    More analyst ratings

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $53,250 worth of shares (20,000 units at $2.66) and was granted 24,000 shares, increasing direct ownership by 40% to 155,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      3/13/25 9:51:29 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $19,250 worth of shares (5,000 units at $3.85), increasing direct ownership by 5% to 111,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      12/9/24 6:16:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    SEC Filings

    See more
    • SEC Form SD filed by Sight Sciences Inc.

      SD - Sight Sciences, Inc. (0001531177) (Filer)

      5/30/25 4:35:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Sight Sciences Inc.

      10-Q - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:16:05 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:08:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Financials

    Live finance-specific insights

    See more
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

      MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg

      3/5/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      11/14/24 11:57:36 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      2/14/24 5:24:02 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sight Sciences Inc.

      SC 13G - Sight Sciences, Inc. (0001531177) (Subject)

      2/13/24 6:52:37 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. was granted 12,767 shares, increasing direct ownership by 8% to 167,767 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:39:13 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Bauerlein Alison sold $45,430 worth of shares (13,066 units at $3.48), decreasing direct ownership by 2% to 636,728 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:38:03 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

      MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences' management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the Investors section of the Company's website at https://investors.sightsciences.com/. About Sight Sciences Sight Sciences is an eyecar

      5/14/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Sight Sciences with a new price target

      UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50

      12/6/24 8:14:13 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences downgraded by Lake Street with a new price target

      Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously

      11/4/24 8:26:06 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Sight Sciences with a new price target

      Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00

      8/21/24 8:27:48 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Gary Burbach to its Board of Directors

      MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

      4/22/25 4:05:00 PM ET
      $BWXT
      $SGHT
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

      11/7/24 4:04:00 PM ET
      $INGN
      $SGHT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Sight Sciences Appoints Matt Link as Chief Commercial Officer

      MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth

      9/11/23 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care